UV/Vis Spectroscopy Crystallinity Detection in Amorphous Pharmaceuticals
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting crystallinity in amorphous pharmaceutical compositions are time-consuming, off-line, and not suitable for real-time monitoring in manufacturing settings, posing challenges in ensuring high-quality pharmaceutical products.
Innovation Solution
A method utilizing UV/vis spectroscopy to generate a predictive model for determining the amount of crystallinity in amorphous solid dispersions or solid-state solutions, involving the measurement of reflectance and/or transmission spectra and processing to derive features correlating with crystallinity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If powder XRD is used to determine residual crystalline material, then measurement precision is improved, but productivity deteriorates due to off-line operation and long analysis time (15 mins to 1 hour)
Solution Approach 1:
The patent replaces the mechanical powder preparation and X-ray diffraction system with an optical Raman spectroscopy system that can perform crystallinity detection without physical sample preparation. The Raman probe directly measures the solid material in the extruder, eliminating milling steps and enabling rapid online analysis that maintains both precision and productivity
Solution Approach 2:
The patent introduces Raman spectroscopy as an intermediary measurement technique that bridges the gap between the need for precise crystallinity measurement and the requirement for rapid throughput. The Raman signal serves as a mediator that correlates with crystalline content while enabling fast, non-destructive analysis that doesn't require sample preparation or lengthy measurement cycles
2Productivity
If Raman spectroscopy is used for in-line manufacturing monitoring, then productivity is improved through faster analysis, but device complexity increases due to laser safety requirements and long integration times
Solution Approach 1:
The patent changes the operational parameters of the Raman spectroscopy system by using higher laser power levels and shorter integration times compared to traditional Raman setups. This parameter optimization enables the system to achieve sufficient signal quality rapidly, reducing the impact of laser safety constraints and making the system suitable for in-line manufacturing monitoring
Solution Approach 2:
The patent implements continuous Raman spectroscopy measurements during the extrusion process, maintaining constant monitoring of crystallinity levels. The system performs uninterrupted spectral acquisitions as material passes through the measurement zone, enabling real-time feedback without stopping the manufacturing process or requiring complex batch-wise analysis protocols
3Reliability
If extensive quality control measures are implemented to meet regulatory standards, then reliability is improved, but loss of time and financial resources increases
Solution Approach 1:
The patent implements a feedback-controlled quality system where Raman spectroscopy continuously monitors crystallinity levels during extrusion, and the process parameters are automatically adjusted based on real-time measurements. This closed-loop feedback enables immediate correction of deviations, ensuring regulatory compliance while reducing the need for extensive post-manufacturing quality control testing
Solution Approach 2:
The patent performs crystallinity assessment during the manufacturing process itself rather than as a separate post-processing step. By measuring and controlling crystallinity in real-time during extrusion, the system ensures quality requirements are met before the product leaves the manufacturing line, eliminating the need for time-consuming separate quality control operations
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for rapid, inexpensive, and reliable detection of crystallinity, enabling improved quality control and manufacturing efficiency by ensuring crystallinity is within acceptable ranges, thus meeting regulatory standards with reduced time and financial burdens.
Implementation Method 1
A method of testing a pharmaceutical composition comprising an API in an amorphous solid dispersion or solid-state solution for crystallinity of the API comprises the steps of; (i) subjecting the dispersion or solution to UV/vis spectroscopy, (ii) measuring a reflectance and/or transmittance spectrum
Data Source
AI summary
Methods of testing pharmaceutical compositions for the presence or absence of active pharmaceutical ingredient (API) crystallinity in an amorphous solid dispersion or solid-state solution using UV/vis spectrometry is provided. Testing may be performed standalone or during manufacturing of a pharmaceutical composition. A predictive model provides for quantitative analysis of the amount of crystalline API based on UV/vis data of corresponding reference samples. Also provided is an apparatus for manufacturing a pharmaceutical composition.